Sign in

NCT06286371Completed

Pelvic Neuro-Angiogenesis in Deep Endometriosis

Pelvic Neuro-Angiogenesis Density in the Presence of Deep Endometriosis and Relationship Between Pelvic Pain Scores

Source: ClinicalTrials.gov · Last updated 29 Jan 2026

Brief summary (registry, in English)

Endometriosis is observed in one out of every ten women in society, causing endometrial cells to be found outside their normal location in the body and proliferate in other locations, leading to fibrosis in the tissue due to the secretion of various factors from the cells. Additionally, the substances secreted by the cells can cause various other changes in the tissue besides fibrosis. Increased neurogenesis and neovascularization are among the primary changes, which occur as a result of the secretion of substances from the cells. Increased neovascularization, neurogenesis, and fibrosis in the tissue lead to the formation of nodular structures in the pelvic region, resulting in pain development in women. Nodular formations in the pelvic region due to endometriosis are especially observed in the rectovaginal space. Despite being small in size, they can induce increased neovascularization and neurogenesis even in healthy peritoneal tissue due to the microenvironment they create, leading to different clinical symptoms clinically. However, it is not known how far these changes occur around the endometriotic nodule in the presence of endometriosis. In this project, in patients operated on due to endometriosis, the density of nerve and vascular structures in the surgical margins of the peritoneal tissue excised along with the nodule, and the synthesis and release of chemical mediators causing pain (e.g., Bradykinin, Substance-P) are evaluated. The aim is to determine the minimum surgical margin where excision should be applied in surgery and to demonstrate any endometriotic changes that may exist in the tissues, even though they may appear macroscopically healthy.

Status (registry)
Completed
Study type
Interventional
Enrollment
15 (actual)
First submitted
22 Feb 2024
Start date
1 Dec 2023
Primary completion date
23 Apr 2025
Lead sponsor
Uludag University
NCT number
NCT06286371

What you commit to

  • Study type: Interventional
  • Participants enrolled: 15
  • From 1 Dec 2023 to the primary completion date, 23 Apr 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients with extensive surgery (hysterectomy, ovariectomy)
  • Patients with previous endometriosis or another pelvic surgery

Other illness

  • Patients with pelvic inflammatory disease history

Other

  • Patients with malignity suspicion
  • Patients with oocyte pick up procedure history

Who the study is looking for

  • Patients with suspicion of deep endometriosis (Physical Examination and MRI)
  • Patients with ineffective response to medical therapy
  • Patients who undergo laparoscopic conservative endometriosis surgery (douglasectomy)

Age in the registry: 18 years to 45 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Uludag University Faculty Hospital
Coordinator of this site? Confirm its status
BursaTurkey (Türkiye)Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.